- Home
- LEVI vs LEGN Comparison
LEVI vs LEGN Comparison
Compare LEVI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEVI
- LEGN
- Stock Information
- Founded
- LEVI 1853
- LEGN 2014
- Country
- LEVI United States
- LEGN United States
- Employees
- LEVI N/A
- LEGN N/A
- Industry
- LEVI Apparel
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- LEVI Consumer Discretionary
- LEGN Health Care
- Exchange
- LEVI Nasdaq
- LEGN Nasdaq
- Market Cap
- LEVI 6.8B
- LEGN 6.0B
- IPO Year
- LEVI 2019
- LEGN 2020
- Fundamental
- Price
- LEVI $17.37
- LEGN $32.66
- Analyst Decision
- LEVI Buy
- LEGN Strong Buy
- Analyst Count
- LEVI 11
- LEGN 13
- Target Price
- LEVI $22.55
- LEGN $80.62
- AVG Volume (30 Days)
- LEVI 1.4M
- LEGN 1.3M
- Earning Date
- LEVI 01-29-2025
- LEGN 03-10-2025
- Dividend Yield
- LEVI 2.99%
- LEGN N/A
- EPS Growth
- LEVI N/A
- LEGN N/A
- EPS
- LEVI 0.38
- LEGN N/A
- Revenue
- LEVI $6,157,900,000.00
- LEGN $520,183,000.00
- Revenue This Year
- LEVI $3.04
- LEGN $120.36
- Revenue Next Year
- LEVI $4.51
- LEGN $67.91
- P/E Ratio
- LEVI $45.78
- LEGN N/A
- Revenue Growth
- LEVI 0.53
- LEGN 122.96
- 52 Week Low
- LEVI $15.16
- LEGN $30.17
- 52 Week High
- LEVI $24.34
- LEGN $70.13
- Technical
- Relative Strength Index (RSI)
- LEVI 48.25
- LEGN 41.28
- Support Level
- LEVI $16.90
- LEGN $30.17
- Resistance Level
- LEVI $17.90
- LEGN $37.92
- Average True Range (ATR)
- LEVI 0.44
- LEGN 2.07
- MACD
- LEVI -0.00
- LEGN 0.12
- Stochastic Oscillator
- LEVI 44.09
- LEGN 32.13
About LEVI Levi Strauss & Co
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver; Europe; and Asia.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.